Table 1.
Effects of agonists injected into the RVLM on LF‐SBP
| Δ LF‐SBP (% total power) | ||
|---|---|---|
| Pre‐F13A | Post‐F13A | |
| Saline | −2.2 ± 2.0 | 0.4 ± 1.3 |
| [Pyr1]apelin‐13 | 13.9 ± 4.3*** | −0.6 ± 1.5†† |
| Pre‐losartan | Post‐losartan | |
| Saline | 3.0 ± 2.0 | 1.0 ± 1.6 |
| [Pyr1]apelin‐13 | 11.5 ± 4.0* | 10.4 ± 2.0* |
| Ang II | 13.9 ± 4.3* | 1.0 ± 1.5‡ |
| Pre‐SR 49059 | Post‐SR 49059 | |
| Saline | 1.3 ± 1.4 | 1.3 ± 1.5 |
| DMSO | 1.1 ± 1.3 | 0.2 ± 1.1 |
| [Pyr1]apelin‐13 | 19.2 ± 3.8***, +++ | 1.1 ± 1.1††† |
| VP | 16.9 ± 5.5***, +++ | 1.1 ± 1.8‡‡ |
| Pre‐dOVT | Post‐dOVT | |
| Saline | 2.8 ± 1.8 | 1.3 ± 0.6 |
| [Pyr1]apelin‐13 | 19.2 ± 1.4* | 17.2 ± 3.8 |
| OT | 35.6 ± 7.5*** | 2.7 ± 1.4‡‡‡ |
| Pre‐kynurenic acid | Post‐kynurenic acid | |
| Saline | 0.8 ± 2.0 | 0.8 ± 1.7 |
| [Pyr1]apelin‐13 | 9.8 ± 1.7* | 8.5 ± 1.1* |
| Glutamate | 23.5 ± 8.1** | −0.8 ± 2.0‡‡ |
| Pre‐bicuculline | Post‐bicuculline | |
| Saline | 0.2 ± 0.3 | 0.1 ± 0.2 |
| [Pyr1]apelin‐13 | 7.3 ± 1.1*** | 4.4 ± 0.8*** |
| Muscimol | −8.5 ± 1.2*** | −0.7 ± 1.0‡‡‡ |
* P < 0.05, ** P < 0.01, *** P < 0.001 vs. saline. + P < 0.05, ++ P < 0.01, +++ P < 0.001 vs. DMSO. † P < 0.05, †† P < 0.01, ††† P < 0.001 [Pyr1]apelin‐13 pre‐ vs. [Pyr1]apelin‐13 post‐antagonist. ‡ P < 0.05, ‡‡ P < 0.01, ‡‡‡ P < 0.001 Agonist pre‐ vs. agonist post‐antagonist.